Select Publications

  1. Paschall R, Quimby JM, Cianciolo RE, McLeland SM, Lunn KF, Elliott J. Assessment of capillary rarefaction in cats with and without CKD. J Vet Int Med. 2023 Feb 17. doi: 10.1111/jvim.16656. Online ahead of print.
  2. Quimby JM, Mcleland SM, Cianciolo RE, Lunn KF, Lulich JP, Erickson AE, Zajic L. Frequency of histologic lesions in the kidney of cats without kidney disease. J Fel Med Surg 2022; doi: 10.1177/1098612X221123768
  3. Cooley CM, Quimby JM, Summers S, Lappin MR. Pilot study evaluating the use of a commercially available oral nutrient supplement in the management of chronic kidney disease in cats. Open J Vet Med. 2022 doi: 4236/ojvm.2021.122002.
  4. Summer S, Quimby JM, Blake A, Keys D, Steiner J, Suchodolski J. Serum and fecal amino acid profiles in cats with chronic kidney disease. Vet Sci. 2022; 9: 84. doi: 10.3390/vetsci9020084.
  5. Quimby JM, Lorbach S, Saffire A, Kennedy A, Wittenberg L, Aarnes TK, Creighton KJ, Jones SE, Paschall RE, King EM, Bruner CE, Wallinger JN, van Haaften K. Serum Concentrations of Gabapentin in Cats with Chronic Kidney Disease. J Fel Med Surg 2022. doi: 10.1177/1098612X221077017.
  6. Navarro I, Summers S, Rishniw M, Quimby J. Cross-sectional survey of non-invasive blood pressure measurement practices in cats by veterinarians. J Fel Med Surg. 2022 doi: 10.1177/1098612X211067015.
  7. Snell C, Winston J, Quimby JM, Diaz-Campos D, Gibson J, Harrison A, Byron J, Rudinsky A. coli probiotic exhibits in vitro growth limiting effects on clinical feline uropathogenic E. coli isolates. Am J Vet Res. 2022 Jun 6;83(7):ajvr.21.07.0096. doi: 10.2460/ajvr.21.07.0096..
  8. Jones S, Quimby JM, Summers S, Adams S, Caney S, Rudinsky A. Survey of defecation habits in apparently healthy and chronic kidney disease cats. J Fel Med Surg. 2022; 24:131-141.
  9. Quimby JM, Erickson AK, McLeland SM, Cianciolo RE, Maranon D, Lunn KF, Elliott J, Lawson JS, Hess AM, Paschall R, Bailey SM. Renal senescence, telomere shortening and nitrosative stress in feline chronic kidney disease. Vet Sci. 2021; 8: 314.
  10. Spenser A, Quimby JM, Price J, MacLane S, Hillsman S, Secoura P, Steiner J, Tolbert KM. Appetite-stimulating effects of once-daily omeprazole in cats with chronic kidney disease: double-blind, placebo-controlled, randomized, crossover trial. J Vet Intern Med. 2021;35: 2705-2712.
  11. Summers SC, Quimby JM, Yao L, Hess A, Broekling C, Lappin MR. Biologic variation of major gut-derived uremic toxins in the serum of healthy adult cats. J Vet Intern Med. 2021: 35: 902-911.
  12. Benson KK, Quimby JM, Shropshire SB, Summers SC, Dowers KL. Evaluation of platelet function in cats with and without kidney disease: a pilot study. J Fel Med Surg.2021; 23: 715-721.
  13. Rayhel L, Quimby JM, Cianciolo RE, Cleroux A, McLeland SM, Franken T. Clinicopathologic and Pathologic Characteristics of Feline Proteinuric Kidney Disease. J Fel Med Surg 2020: 22: 1219-1229.
  14. Coyne M, Szlosek D, Robertson J, Quimby JM, Mack R, Ogeer J, Clements C, McCrann D. A retrospective evaluation of the relationship between symmetric dimethylarginine, creatinine and body weight in hyperthyroid cats. PloSOne 2020: 15; e0227964.
  15. Benson KK, Quimby JM, Dowers KL, Sieberg LG, Daniels JB, Langston CE, Gustafson DL, Lunghofer PJ. Pilot study of side effects and serum and urine concentrations of amoxicillin-clavulanic acid in azotemic and non-azotemic cats. J Fel Med Surg 2020; 22: 729-735. 2020 JFMS Best Resident Paper Award.
  16. Rayhel L, Quimby JM, Green E, Parker V, Bai S. Inter- and intra-rater reliability of computed tomographic measurement of feline epaxial muscle area. J Fel Med Surg 2020; 22: 721-728.
  17. Summers S, Quimby JM, Phillips, RK, Stockman J, Isaiah A, Lidbury J, Steiner J, Sucholdolski J. Preliminary evaluation of fecal fatty acid concentrations in cats with chronic kidney disease and correlation with indoxyl sulfate and p-cresol sulfate. J Vet Intern Med 2020; 34: 206-215.
  18. Sieberg LG, Quimby JM. Retrospective study of the efficacy of oral potassium supplementation in cats with kidney disease. J Fel Med Surg. 2020; 22: 539-543.
  19. Quimby JM, Benson KK, Summers SC, Saffire A, Herndon AK, Bai S, Gustafson DL. Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease. J Fel Med Surg 2020; 22: 376-383.
  20. Ledesma-Feliciano C, Troyer RM, Zheng X, Miller C, Cianciolo R, Bordicchia M, Dannemiller N, Gagne R, Beatty J, Quimby J, Löchelt M, VandeWoude S. Feline foamy virus infection: characterization of experimental infection and prevalence of natural infection in domestic cats with and without chronic kidney disease. Viruses. 2019; 11: 662. doi: 10.3390/v11070662
  21. McLeland SM, Quimby JM. Lappin MR. Alpha-enolase patterns in the renal tissue of cats with and without chronic kidney disease. Vet Immunol Immunopathol. 2019; 212: 23-36.
  22. Poole O’Banion M, Quimby JM, Hu T, Labelle D, Buhles W. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. J Vet Pharm Ther 2019; 42: 179-188.
  23. Summers S, Quimby JM, Isaiah A, Suchodolski JS, Lunghofer PJ, Gustafson DL. The fecal microbiome and serum concentrations of indoxyl sulfate and p-cresol sulfate in cats with chronic kidney disease. J Vet Intern Med. 2019; 33: 662-669.
  24. Fitzpatrick RL, Quimby JM, Benson KK, Ramirez D, Sieberg L, Wittenburg LA, Gustafson DL. In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. J Vet Int Med 2018; 32: 1951-1957.
  25. Buhles W, Quimby JM, Labelle D, Williams VS. Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. J Vet Pharm Ther 2018; 41: 644-651.
  26. Cooley C, Quimby JM, Caney SMA, Sieberg L, Survey of subcutaneous fluid practices in cats with chronic kidney disease. J Fel Med Surg 2018:20: 884-890.
  27. Quimby, JM, Borjesson, DL. Mesenchymal stem cell therapy in cats: Current knowledge and future potential. J Fel Med Surg 2018:20: 208-216. Review.
  28. Herndon A, Quimby JM, Sieberg L, Davis L, Caress A, Ligas S, Hansen RJ, Wittenburg LA, Gustafson DL. Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. J Fel Med Surg 2018; 20: 721-727.
  29. Zajic LB, Herndon A, Sieberg L, Caress A, Morgan P, Hansen RJ, Wittenburg LA, Gustafson DL, Quimby JM. Investigation of the pharmacokinetics of transdermal ondansetron in normal purpose-bred cats. J Fel Med Surg 2017; 19: 1245-1248.
  30. Zajic LB, Webb TL, Webb P, Coy J, Dow SW, Quimby JM. Comparison of proliferative and immunomodulatory potential of adipose-derived mesenchymal stem cells from young and geriatric cats. J Fel Med Surg 2017; 19: 1096-1102.
  31. Whitehouse W, Quimby JM, Wan S, Monaghan K, Robbins R, Trepanier L. Urinary F2-isoprostanes in cats with IRIS stages 1 to 4 chronic kidney disease. J Vet Int Med 2017; 31: 449-456.
  32. Felumlee AE, Marolf AJ, Randall EK, Bachand AM, Quimby JM. Intra- and interobserver variability of glomerular filtration rate determination in cats with chronic kidney disease via gamma camera uptake of TC-99M-DTPA. Vet Rad Ultrasound 2017; 58: 90-99.
  33. Benson KK, Zajic LB, Morgan P, Brown S, Hansen RJ, Lunghofer PJ, Wittenburg LA Gustafson DL, Quimby JM. Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. J Fel Med Surg 2017; 19: 998-1006.
  34. Quimby JM, Dowers K, Herndon AK, Randall EK. Renal pelvic and ureteral ultrasonographic characteristics of cats with chronic kidney disease in comparison to normal cats, and cats with pyelonephritis or ureteral obstruction. J Fel Med Surg 2017; 19: 784-790.
  35. Fitzpatrick RL, Wittenburg LA, Hansen RJ, Gustafson DL, Quimby JM. Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease and cats with liver disease. J Vet Pharmacol Ther 2016; 39: 350-5.
  36. Quimby, JM, Lappin MR. Evaluating sucralfate as a phosphate binder in normal cats and cats with chronic kidney disease. J Am Anim Hosp Assoc 2016; 52: 8-12.
  37. Ferguson LE, McLean MK, Bates J, Quimby JM. Mirtazapine toxicity in cats: Retrospective study of 84 cases (2006-2011). J Fel Med Surg 2016; 18: 868-874.
  38. Quimby JM, Webb TL, Randall R, Marolf A, Valdes-Martinez A, Dow SW. Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats. J Fel Med Surg 2016; 18: 165-171.
  39. Quimby JM, Dow SW. Novel treatment strategies for feline chronic kidney disease: a critical look at the potential of mesenchymal stem cell therapy. Vet J 2015: 204: 241-246.
  40. McLeland SM, Cianciolo R, Duncan C, Quimby JM. A comparison of biochemical and histopathologic staging in cats with chronic kidney disease. Vet Path 2015; 28: 827-837.
  41. Quimby JM, Brock WT, Moses K, Bolotin D, Patricelli K. Maropitant for the management of vomiting and inappetence associated with chronic kidney disease in cats. J Fel Med Surg: 2015;17: 692-697.
  42. McLeland SM, Lunn KF, Duncan CG, Refsal KR, Quimby JM. Relationship between serum creatinine, serum gastrin, calcium-phosphorus product and uremic gastropathy in cats with chronic kidney disease. J Vet Int Med 2014; 28: 827-837.
  43. Quimby JM, Lake RC, Hansen RJ, Lunghofer PJ, Gustafson DL. Oral, subcutaneous and intravenous pharmacokinetics of ondansetron in healthy cats. J Vet Pharmacol Ther 2014; 37: 348-353.
  44. Quimby JM, Lunn KF. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J 2013; 197: 651-654.
  45. Quimby JM, Maranon DG, Battaglia CLR, McLeland SM, Brock WT, Bailey SM. Feline chronic kidney disease is associated with shortened telomeres and increased cellular senescence. Am J Physiol Renal Physiol 2013; 305: F295-303.
  46. Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Research & Therapy 2013; 4: 48.
  47. McLeland SM, Imhoff DJ, Thomas M, Powers BE, Quimby JM. Subcutaneous fluid port-associated soft tissue sarcoma in a cat. J Fel Med Surg 2013; 15: 917-920.
  48. Habenicht LM, Webb TL, Clauss LA, Dow SW, Quimby JM. Urinary cytokine levels in apparently healthy cats and cats with chronic kidney disease. J Fel Med Surg 2013; 15: 99-104.
  49. Webb TL, Quimby JM, Dow SW. In vitro comparison of feline bone-marrow-derived and adipose tissue-derived mesenchymal stem cells. J Fel Med Surg 2011; 14: 165-168.
  50. Quimby JM, Gustafson DL, Lunn KF. The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. J Vet Int Med 2011; 25: 985-988.
  51. Quimby JM, Webb TL, Gibbons D, Dow SW. Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Fel Med Surg 2011; 13(6):418-26.
  52. Catbagan D, Quimby JM, Bratley J, Sonius C, Mich P, Vogel P, Mama K. Comparison of the efficacy of an oral transmucosal buprenorphine and sustained release subcutaneous buprenorphine in cats post-surgical ovariohysterectomy. Am J Vet Res 2011; 72:461-466
  53. Quimby JM, Smith ML, Lunn KF. Evaluation of effects of hospital visit stress on physiologic parameters in the cat. J Fel Med Surg 2010; 13: 733-737.
  54. Quimby JM, Samber BJ, Gustafson DL, Lunn KF. Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. J Vet Pharmacol Ther 2010: 34: 388-396.